KSPHF

Kissei Pharmaceutical Co. Ltd

KSPHF, USA

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. Kissei Pharmaceutical Co., Ltd. was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan.

https://www.kissei.co.jp

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

Semiannual

Rate:

0.4182

Next Payout:

Jun 1, 2026

Yield:

6.2024 %
KSPHF
stock
KSPHF

Nomura Maintains KISSEI PHARMACEUTICAL CO(KSPHF.US) With Buy Rating, Raises Target Price to $33.81 富途资讯

Read more →

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

12.32

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.78

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

1.55 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

1.25 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

33.94

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Kissei Pharmaceutical Co. Ltd

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

77.13

Latest Release

Date

2025-09-30

EPS Actual

0.5341

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(2)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(8)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.